Pseudomonas vaccine - Provalis

Drug Profile

Pseudomonas vaccine - Provalis

Alternative Names: Psuedostat

Latest Information Update: 16 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Provalis
  • Developer Provalis; University of Newcastle, Australia
  • Class Bacterial vaccines; Pseudomonas vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bronchiectasis; Chronic bronchitis; Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections

Most Recent Events

  • 17 Feb 2003 Suspended - Phase-I for Cystic fibrosis-associated respiratory tract infections in Australia (PO)
  • 17 Feb 2003 Suspended - Preclinical for Pseudomonal infections in Australia (PO)
  • 06 Sep 2002 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top